Biologically Active Small Molecules

BW 245C is a selective agonist for the DP1 receptor. The Ki of BW 245C for the inhibition of [3H]-PGD2 binding to isolated human platelet membranes is 0.

BW 245C is a selective agonist for the DP1 receptor. The Ki of BW 245C for the inhibition of [3H]-PGD2 binding to isolated human platelet membranes is 0.

BW 246C is the less active C-8 diastereomer of the DP1 receptor agonist BW 245C. The activity of BW 245C is 70-fold greater than that of BW 246C.

BW 246C is the less active C-8 diastereomer of the DP1 receptor agonist BW 245C. The activity of BW 245C is 70-fold greater than that of BW 246C.

BW 246C is the less active C-8 diastereomer of the DP1 receptor agonist BW 245C. The activity of BW 245C is 70-fold greater than that of BW 246C.

An anxiolytic compound that causes hyperphagia, which likely due to its 10-fold selectivity for the 5-HT2B receptor direct infusion of 1-3 &microg into the cerebral ventricles of rats evokes maximal behavioral responses.

An anxiolytic compound that causes hyperphagia, which likely due to its 10-fold selectivity for the 5-HT2B receptor direct infusion of 1-3 &microg into the cerebral ventricles of rats evokes maximal behavioral responses.

An anxiolytic compound that causes hyperphagia, which likely due to its 10-fold selectivity for the 5-HT2B receptor direct infusion of 1-3 &microg into the cerebral ventricles of rats evokes maximal behavioral responses.

An anxiolytic compound that causes hyperphagia, which likely due to its 10-fold selectivity for the 5-HT2B receptor direct infusion of 1-3 &microg into the cerebral ventricles of rats evokes maximal behavioral responses.

A dual inhibitor of 5-LO and COX pathways, inhibiting 5-LO, COX-1, and COX-2 (IC₅₀s = 0.75 &muM, 0.65 &mug/ml, and 1.2 &mug/ml, respectively) may also inhibit other LO pathways in vivo.

A dual inhibitor of 5-LO and COX pathways, inhibiting 5-LO, COX-1, and COX-2 (IC₅₀s = 0.75 &muM, 0.65 &mug/ml, and 1.2 &mug/ml, respectively) may also inhibit other LO pathways in vivo.

A dual inhibitor of 5-LO and COX pathways, inhibiting 5-LO, COX-1, and COX-2 (IC₅₀s = 0.75 &muM, 0.65 &mug/ml, and 1.2 &mug/ml, respectively) may also inhibit other LO pathways in vivo.